drug

ritlecitinib

Marketedupdated 5mo ago

by $PFE PFIZER INC

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying ritlecitinib

phase2Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remissioncompletedn=62
phase2Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)active not recruitingn=78
phase2A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.active not recruitingn=128
—Litfulo Capsules Special Investigationactive not recruitingn=664
phase3A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areatarecruitingn=336
—Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the UScompletedn=300
phase2A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.recruitingn=200
—A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settingscompletedn=123

Patent cliff

source: FDA Orange Book

first barrier falls

Jun 23, 2028

~1.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

Oct 17, 2041compositionUS 12116368
Dec 3, 2034method-of-use (U-3994)US 12077533
Dec 3, 2034compositionUS 9617258

FDA exclusivities (1)

Jun 23, 2028NCENew Chemical Entity (5y)1.7y

News(2)

Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.
biopharma_dive · 2mo ago
Pfizer's Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182M
Pfizer reports Phase 3 wins for Litfulo: The drug succeeded in two trials for active and stable nonsegmental vitiligo, an autoimmune condition that causes skin to progressively lose its color. One ...
endpoints · 2mo ago

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

ritlecitinib

Marketedupdated 5mo ago

by $PFE PFIZER INC

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying ritlecitinib

phase2Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remissioncompletedn=62
phase2Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)active not recruitingn=78
phase2A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.active not recruitingn=128
—Litfulo Capsules Special Investigationactive not recruitingn=664
phase3A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areatarecruitingn=336
—Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the UScompletedn=300
phase2A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.recruitingn=200
—A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settingscompletedn=123

Patent cliff

source: FDA Orange Book

first barrier falls

Jun 23, 2028

~1.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

Oct 17, 2041compositionUS 12116368
Dec 3, 2034method-of-use (U-3994)US 12077533
Dec 3, 2034compositionUS 9617258

FDA exclusivities (1)

Jun 23, 2028NCENew Chemical Entity (5y)1.7y

News(2)

Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.
biopharma_dive · 2mo ago
Pfizer's Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182M
Pfizer reports Phase 3 wins for Litfulo: The drug succeeded in two trials for active and stable nonsegmental vitiligo, an autoimmune condition that causes skin to progressively lose its color. One ...
endpoints · 2mo ago

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

ritlecitinib

all catalysts(0)

Trials studying ritlecitinib

Patent cliff

patents (3)

FDA exclusivities (1)

News(2)

Report a data issue

comments(0)

ritlecitinib

all catalysts(0)

Trials studying ritlecitinib

Patent cliff

patents (3)

FDA exclusivities (1)

News(2)

Report a data issue

comments(0)